ACCELERATED CHEMOTHERAPY WITH OR WITHOUT GM-CSF FOR SMALL-CELL LUNG-CANCER - A NONRANDOMIZED PILOT-STUDY

被引:20
作者
ARDIZZONI, A
SERTOLI, MR
CORCIONE, A
PENNUCCI, MC
BALDINI, E
INTRA, E
FERRARINI, M
ROSSO, R
MAZZANTI, P
PISTOIA, V
机构
[1] IST NAZL RIC CANC,DEPT CLIN IMMUNOL,GENOA,ITALY
[2] OSPED GALLIERA,DEPT CLIN PATHOL,GENOA,ITALY
[3] IST SCI G GASLINI,DIV PEDIAT HEMATOL ONCOL,GENOA,ITALY
[4] SCHERING PLOUGH CORP,MILAN,ITALY
关键词
D O I
10.1016/0277-5379(90)90614-Y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Two series of five consecutive patients with small cell lung cancer were treated with an "accelerated" chemotherapy regimen of cyclophosphamide-doxorubicin-vincristine (CAV) and cisplatin-etoposide (PE) alternated possibly every week. In the first group of patients (median age 49 years, range 46-52) recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) was given as soon as grade IV leukopenia occurred, while in the second group (median age 59 years, 55-68) no growth factor was administered. The mean interval between chemotherapy courses and the mean duration of chemotherapy were 10 and 57 days, respectively, in the patients supported with GM-CSF compared with 13 and 72 days in the control group. One GM-CSF treated patient was withdrawn after the third cycle because of severe toxicity. The mean white blood cell and platelet nadirs were 600 and 46 000/mu-l in the first group vs. 840 and 105 000/mu-l in the controls. Overall chemotherapy dose-intensity was increased by two fold in the patients given GM-CSF compared with a 1.5 fold increase in the control patients. In all cases, irrespective of their treatment, there was an impaired colony forming capacity of circulating and marrow haemopoietic progenitor cells when grade IV leukopenia occurred, with recovery after the end of leukopenia. This pilot study suggests that accelerated CAV/PE chemotherapy is feasible both with and without GM-CSF. Different GM-CSF schedules as well as combinations of different haemopoietic growth factors may further improve dose-intensity.
引用
收藏
页码:937 / 941
页数:5
相关论文
共 18 条
[1]   THE USE OF GRANULOCYTE COLONY-STIMULATING FACTOR TO INCREASE THE INTENSITY OF TREATMENT WITH DOXORUBICIN IN PATIENTS WITH ADVANCED BREAST AND OVARIAN-CANCER [J].
BRONCHUD, MH ;
HOWELL, A ;
CROWTHER, D ;
HOPWOOD, P ;
SOUZA, L ;
DEXTER, TM .
BRITISH JOURNAL OF CANCER, 1989, 60 (01) :121-125
[2]   SUPERIORITY OF ALTERNATING NON-CROSS-RESISTANT CHEMOTHERAPY IN EXTENSIVE SMALL-CELL LUNG-CANCER - A MULTICENTER, RANDOMIZED CLINICAL-TRIAL BY THE NATIONAL-CANCER-INSTITUTE-OF-CANADA [J].
EVANS, WK ;
FELD, R ;
MURRAY, N ;
WILLAN, A ;
COY, P ;
OSOBA, D ;
SHEPHERD, FA ;
CLARK, DA ;
LEVITT, M ;
MACDONALD, A ;
WILSON, K ;
SHELLEY, W ;
PATER, J .
ANNALS OF INTERNAL MEDICINE, 1987, 107 (04) :451-458
[3]  
GOLDIE JH, 1984, CANCER RES, V44, P3643
[4]  
HIDE DC, 1984, CANCER, V54, P2722
[5]   MACOP-B CHEMOTHERAPY FOR THE TREATMENT OF DIFFUSE LARGE-CELL LYMPHOMA [J].
KLIMO, P ;
CONNORS, JM .
ANNALS OF INTERNAL MEDICINE, 1985, 102 (05) :596-602
[6]   CLINICAL USE OF RECOMBINANT HUMAN HEMATOPOIETIC GROWTH-FACTORS [J].
LAVER, J ;
MOORE, MAS .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (18) :1370-1382
[7]  
MORRISSEY PJ, 1988, J IMMUNOL, V140, P1910
[8]  
MURRAY N, 1987, SEMIN ONCOL, V14, P20
[9]   MOLECULAR-CLONING AND EXPRESSION OF CDNA FOR HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR [J].
NAGATA, S ;
TSUCHIYA, M ;
ASANO, S ;
KAZIRO, Y ;
YAMAZAKI, T ;
YAMAMOTO, O ;
HIRATA, Y ;
KUBOTA, N ;
OHEDA, M ;
NOMURA, H ;
ONO, M .
NATURE, 1986, 319 (6052) :415-418
[10]  
PISTOIA V, 1989, BLOOD, V74, P156